Market revenue in 2020 | USD 21.4 million |
Market revenue in 2028 | USD 41.0 million |
Growth rate | 8.5% (CAGR from 2020 to 2028) |
Largest segment | Dermatology disease |
Fastest growing segment | Neurological Disorders |
Historical data covered | 2016 - 2019 |
Base year for estimation | 2020 |
Forecast period covered | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Dermatology disease was the largest segment with a revenue share of 20.09% in 2020. Horizon Databook has segmented the Middle East & Africa rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
MEA accounted for the lowest revenue share in 2020. This can be attributed to its slow economic growth coupled with low awareness level in the country. Furthermore, neglected tropical diseases are major focus of health goals in the countries such as South Africa & Nigeria, leading to lower share. However.
Global increase in awareness pertaining to rare & ultra rare conditions is anticipated to positively impact the revenue growth in this country. In addition, presence of business footprints of global companies in the region is anticipated to significantly benefit the revenue in this regional market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa rare disease genetic testing market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account